Recent news includes an insider sale of shares by the CEO in 2025 and various market and sector news unrelated directly to NIKA's operations.

• The CEO of NIKA sold 2,000,000 shares as reported on March 19, 2025 [N1].
• Recent news coverage includes broader market topics such as AI sell-offs, earnings reports of other companies, and commodity price movements, with no direct operational updates on NIKA [N1][N2][N3][N4][N5][N6][N7][N8].

NIKA's exclusive rights to patented pharmaceutical products and dietary supplements, combined with its strategic partnerships and manufacturing foothold in Europe, Asia, and Africa, provide a foundation for potential growth in specialized therapeutic areas. The company's emerging growth status allows regulatory flexibility that may support operational development.

NIKA faces significant liquidity challenges, with a very low current ratio and cash ratio as of June 30, 2026, and substantial current liabilities relative to assets. The company reported a net loss and no revenue in recent periods, indicating ongoing operational and financial risks. Lack of formal insider trading policies and limited executive team size may pose governance risks. The company's business model depends heavily on successful commercialization of niche products, which carries inherent market and regulatory risks.

NIKA's moat is based on exclusive rights agreements for proprietary pharmaceutical products and dietary supplements, including patented technologies such as the Inactivated Pepsin Fraction platform. Its controlling stake in Nika Europe, Ltd. provides manufacturing capabilities in multiple regions. The company's partnerships and intellectual property rights create barriers to entry for competitors in its niche product areas.

• Liquidity Risk: As of June 30, 2026, NIKA's current ratio is 0.03 and cash ratio is 0.01, indicating potential difficulties in meeting short-term obligations given current liabilities far exceed current assets.
• Operational Risk: The company reported no revenue for fiscal year 2024 and a net loss of $19.694 million for Q2 2026, reflecting challenges in generating sustainable income from its pharmaceutical and supplement products.
• Regulatory and Market Risk: NIKA's business depends on exclusive rights and patents for specialized products, which may face regulatory hurdles, market acceptance issues, and competition.
• Governance Risk: NIKA operates with a small executive team and has not adopted formal insider trading policies as of the end of 2025, which may affect compliance and oversight.

• NIKA Pharmaceuticals, Inc. is incorporated in Colorado since June 6, 2000.
• The company changed its business focus following a change of control, signing exclusive rights agreements for production and distribution of pharmaceutical and dietary supplement products.
• NIKA has exclusive rights agreements with VITAL FE Joint Stock Company for Thymus Nuclear Glycoprotein (TNG) production and distribution for 15 years starting April 7, 2022.
• TNG has undergone Phase III clinical trials for HIV treatment showing significant results.
• NIKA has exclusive rights agreements with MICAR 11 LTD for two dietary supplements, Carotilen and Physiolong, also for 15 years starting April 7, 2022.
• The company has a joint business agreement with Immunotech Laboratories BG, Ltd. for registration, production, and distribution of medicinal products based on the Inactivated Pepsin Fraction platform with U.S. patents, for 9 years starting August 1, 2022, with automatic renewal.
• NIKA has a cooperation agreement with Nika BioTechnology, Inc. for joint development and cost sharing of prescription drugs and dietary supplements, with net profits shared equally, for 15 years starting August 1, 2022.
• NIKA signed an exclusive rights agreement for six additional dietary supplements for global territories on August 31, 2022.
• The company acquired a 40% stake in Nika Europe, Ltd. on October 11, 2022, which is preparing to build a pharmaceutical factory for drug production in various forms.
• Following a merger with Nika BioTechnology, Inc. effective April 12, 2024, NIKA holds an 80% controlling interest in Nika Europe, Ltd.
• The company’s common stock is listed on OTCQB under the symbol NIKA since December 9, 2024.
• NIKA qualifies as an emerging growth company and avails certain disclosure exemptions under the Securities Act.
• As of June 30, 2026, NIKA reported cash and equivalents of $2.932 million and current assets of $9.942 million, with current liabilities of $340.624 million, resulting in a current ratio of 0.03 and cash ratio of 0.01.
• The company reported a net loss of $19.694 million for the quarter ended June 30, 2026, with zero reported revenue for fiscal year 2024.
• NIKA does not have formal insider trading policies as of December 31, 2025, and operates with two executive officers.
• There are no material legal proceedings pending or threatened against the company or its officers.
• An insider sale of 2,000,000 shares by the CEO was reported on March 19, 2025.
• Recent news coverage relevant to NIKA includes insider share sales and broader market and sector news but no direct operational updates.